Your browser is no longer supported. Please, upgrade your browser.
Settings
UROV Urovant Sciences Ltd. daily Stock Chart
UROV [NASD]
Urovant Sciences Ltd.
Index- P/E- EPS (ttm)-3.58 Insider Own75.40% Shs Outstand30.66M Perf Week7.66%
Market Cap310.28M Forward P/E- EPS next Y-3.70 Insider Trans- Shs Float7.48M Perf Month29.91%
Income-108.50M PEG- EPS next Q-1.15 Inst Own23.10% Short Float10.35% Perf Quarter22.82%
Sales- P/S- EPS this Y-259.00% Inst Trans5.14% Short Ratio19.79 Perf Half Y-10.20%
Book/sh1.57 P/B6.45 EPS next Y8.00% ROA-142.40% Target Price24.00 Perf Year-
Cash/sh2.04 P/C4.97 EPS next 5Y- ROE-199.20% 52W Range4.05 - 14.49 Perf YTD53.57%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-30.16% Beta-
Dividend %- Quick Ratio6.20 Sales past 5Y- Gross Margin- 52W Low149.57% ATR0.82
Employees39 Current Ratio6.20 Sales Q/Q- Oper. Margin- RSI (14)62.03 Volatility9.96% 9.28%
OptionableNo Debt/Eq0.29 EPS Q/Q9.90% Profit Margin- Rel Volume2.26 Prev Close9.54
ShortableYes LT Debt/Eq0.29 EarningsAug 13 AMC Payout- Avg Volume39.12K Price10.12
Recom1.80 SMA2012.32% SMA5017.79% SMA20015.99% Volume88,364 Change6.08%
Mar-15-19Initiated SunTrust Buy $24
Mar-11-19Initiated H.C. Wainwright Buy $28
Oct-22-18Initiated JP Morgan Overweight $21
Oct-22-18Initiated Jefferies Buy $19
Sep-06-19 09:00AM  Urovant Sciences Parent Company, Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create Broad Strategic Alliance Business Wire +6.28%
Aug-13-19 08:23PM  Urovant Sciences Ltd (UROV) Q1 2019 Earnings Call Transcript Motley Fool
04:05PM  Urovant Sciences Reports 2019 First Fiscal Quarter Financial Results Business Wire
Aug-06-19 08:00AM  Urovant Sciences to Report 2019 First Fiscal Quarter Financial Results Business Wire
Jun-29-19 06:08PM  Heres What Hedge Funds Think About Urovant Sciences Ltd. (UROV) Insider Monkey
Jun-20-19 08:25AM  Urovant Sciences Ltd. (NASDAQ:UROV): Immense Growth Potential? Simply Wall St.
Jun-13-19 04:05PM  Urovant Sciences Reports Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019 Business Wire -6.09%
02:30PM  Urovant Sciences Ltd. to Host Earnings Call ACCESSWIRE
Jun-06-19 08:00AM  Urovant Sciences to Report Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019 Business Wire
Jun-03-19 08:00AM  Urovant Sciences to Present at Annual Roivant Pipeline Day Business Wire
May-30-19 08:00AM  Urovant Sciences to Present at the Jefferies 2019 Healthcare Conference Business Wire
May-06-19 08:00AM  Urovant Sciences Presents Positive Pivotal Data for Vibegron During Plenary Session at American Urological Association Annual Meeting Business Wire
Apr-29-19 08:00AM  Urovant Sciences to Present Late-Breaking Data on Vibegron During Plenary Session at the American Urological Association Annual Meeting Business Wire
Mar-27-19 08:00AM  Urovant Sciences Initiates Phase 3 Clinical Program with Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia Business Wire -5.08%
Mar-19-19 04:09PM  Here's Why Urovant Sciences Got Whacked on "Positive" Clinical Trial Data Motley Fool -20.63%
08:00AM  Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder Business Wire
Mar-18-19 04:05PM  Urovant Sciences to Announce Topline Results from the EMPOWUR Phase 3 Study of Vibegron in Patients with Overactive Bladder Business Wire
Mar-07-19 08:00AM  Urovant Sciences to Present at the Cowen and Company 39th Annual Healthcare Conference Business Wire
Mar-06-19 08:00AM  Urovant Sciences Appoints James Robinson to its Board of Directors Business Wire
Feb-26-19 08:14PM  Codexis Inc (CDXS) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-22-19 05:20PM  Urovant Sciences Enters into Flexible Agreement for up to $100 Million Debt Financing with Hercules Capital Business Wire
Feb-13-19 04:05PM  Urovant Sciences Reports Financial Results for the Third Fiscal Quarter Ended December 31, 2018 Business Wire
Feb-06-19 08:00AM  Urovant Sciences to Report 2018 Third Fiscal Quarter Financial Results Business Wire
Jan-15-19 08:00AM  Urovant Sciences to Host R&D Day for Investors and Analysts on February 7, 2019 Business Wire
Jan-03-19 08:00AM  Urovant Sciences Initiates Patient Enrollment in Phase 2a Clinical Trial for Vibegron in Patients with Abdominal Pain Due to Irritable Bowel Syndrome Business Wire
Jan-02-19 08:00AM  Roivant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire +6.22%
Dec-19-18 08:00AM  Urovant Sciences to Present at the J.P. Morgan 37th Annual Healthcare Conference Business Wire
Nov-19-18 08:00AM  Urovant Sciences Announces Participation in Piper Jaffray Healthcare Conference Business Wire
Nov-12-18 04:05PM  Urovant Sciences Reports Financial Results for the Second Fiscal Quarter Ended September 30, 2018 and Provides Corporate Update Business Wire
Nov-08-18 08:00AM  Urovant Sciences Completes Patient Enrollment in Phase 3 Pivotal Trial Studying Vibegron for Overactive Bladder Business Wire
Nov-05-18 08:00AM  Urovant Sciences to Report 2018 Second Fiscal Quarter Financial Results Business Wire -6.32%
Nov-01-18 08:00AM  Urovant Sciences Announces Publication of Phase 2b Data for Vibegron in European Urology Business Wire -6.47%
Oct-11-18 06:41PM  Andreas Halvorsen Discloses Stake in Urovant Sciences GuruFocus.com
Sep-27-18 05:24PM  [$$] Gormley's Take: Urovant Sciences IPO Draws Attention to Urology Market The Wall Street Journal
Sep-26-18 11:00PM  Urovant Sciences Ltd. Announces Pricing of Initial Public Offering PR Newswire
Sep-22-18 04:15PM  The IPO Outlook For The Week: Smart Appliances, A Language App and Drugmakers Benzinga
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. The company is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. The company was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.